Portal de Periódicos da CAPES

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

2014; Elsevier BV; Volume: 123; Issue: 21 Linguagem: Inglês

10.1182/blood-2014-02-548610

1528-0020

Sarah E. M. Herman, Rashida Z. Mustafa, Jennifer Gyamfi, Stefania Pittaluga, Stella Chang, Betty Chang, Mohammed Farooqui, Adrian Wiestner,

Immunodeficiency and Autoimmune Disorders

Key Points Ibrutinib inhibits both BCR and NF-κB signaling in lymph node and bone marrow resident CLL cells. Rapid and sustained reduction of cellular activation and tumor proliferation was achieved in all anatomic compartments.